MY151322A - Management of breakthrough bleeding in extended hormonal contraceptive regimens - Google Patents

Management of breakthrough bleeding in extended hormonal contraceptive regimens

Info

Publication number
MY151322A
MY151322A MYPI20051728A MY151322A MY 151322 A MY151322 A MY 151322A MY PI20051728 A MYPI20051728 A MY PI20051728A MY 151322 A MY151322 A MY 151322A
Authority
MY
Malaysia
Prior art keywords
management
hormonal contraceptive
breakthrough bleeding
contraceptive regimens
extended
Prior art date
Application number
Other languages
English (en)
Inventor
Sachse Andreas
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY151322(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MY151322A publication Critical patent/MY151322A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
MYPI20051728 2004-04-30 2005-04-19 Management of breakthrough bleeding in extended hormonal contraceptive regimens MY151322A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
MY151322A true MY151322A (en) 2014-05-15

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20051728 MY151322A (en) 2004-04-30 2005-04-19 Management of breakthrough bleeding in extended hormonal contraceptive regimens

Country Status (29)

Country Link
US (3) US8163721B2 (cg-RX-API-DMAC7.html)
EP (1) EP1747001B1 (cg-RX-API-DMAC7.html)
JP (4) JP2007535519A (cg-RX-API-DMAC7.html)
KR (4) KR20130022425A (cg-RX-API-DMAC7.html)
CN (1) CN103127156A (cg-RX-API-DMAC7.html)
AR (1) AR048722A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005237255B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510493A (cg-RX-API-DMAC7.html)
CA (1) CA2562296A1 (cg-RX-API-DMAC7.html)
CR (1) CR8709A (cg-RX-API-DMAC7.html)
DK (1) DK1747001T3 (cg-RX-API-DMAC7.html)
EA (2) EA031227B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066999A (cg-RX-API-DMAC7.html)
ES (1) ES2704999T3 (cg-RX-API-DMAC7.html)
HU (1) HUE041475T2 (cg-RX-API-DMAC7.html)
IL (1) IL178458A (cg-RX-API-DMAC7.html)
LT (1) LT1747001T (cg-RX-API-DMAC7.html)
MX (1) MXPA06012567A (cg-RX-API-DMAC7.html)
MY (1) MY151322A (cg-RX-API-DMAC7.html)
NO (1) NO341685B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ586107A (cg-RX-API-DMAC7.html)
PA (1) PA8631801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20060467A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201701904TA (cg-RX-API-DMAC7.html)
SI (1) SI1747001T1 (cg-RX-API-DMAC7.html)
SV (1) SV2006002100A (cg-RX-API-DMAC7.html)
TW (1) TWI374735B (cg-RX-API-DMAC7.html)
UY (1) UY28875A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005105103A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
GB2475013A (en) * 2008-09-16 2011-05-04 Playtex Products Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010042607A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
SI3310346T1 (sl) 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
SMT201800232T1 (it) 2015-06-18 2018-07-17 Mithra Pharmaceuticals S A Unita' di dosaggio orodispersibile contenente un componente di estetrolo
LT3310333T (lt) 2015-06-18 2020-06-25 Estetra Sprl Burnoje dirperguojama vaisto formą, turinti estetrolio komponentą
PT3310345T (pt) 2015-06-18 2021-05-28 Estetra Sprl Comprimido orodispersível contendo estetrol
EP3313408B1 (en) * 2015-06-23 2023-12-06 Laboratorios Leon Farma SA Drospirenone-based contraceptive for a female patient affected with excess weight
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
DK3518933T4 (da) 2016-09-30 2025-04-22 Takeda Pharmaceuticals Co Fremgangsmåder til behandling af uterusfibromer og endometriose
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
CA2261689A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
RS50262B (sr) 1999-08-31 2009-07-15 Bayer Schering Pharma Aktiengesellschaft, Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
EA016625B1 (ru) 2012-06-29
SG10201701904TA (en) 2017-05-30
NO341685B1 (no) 2017-12-18
WO2005105103A2 (en) 2005-11-10
AR048722A1 (es) 2006-05-17
LT1747001T (lt) 2019-01-25
JP2015187157A (ja) 2015-10-29
JP6153967B2 (ja) 2017-06-28
KR20130022425A (ko) 2013-03-06
KR20150058555A (ko) 2015-05-28
EA201200377A8 (ru) 2018-01-31
BRPI0510493A (pt) 2007-11-13
KR20070004919A (ko) 2007-01-09
IL178458A (en) 2016-08-31
CR8709A (es) 2007-08-28
EA031227B1 (ru) 2018-12-28
EA201200377A1 (ru) 2012-08-30
MXPA06012567A (es) 2006-12-15
TW200603781A (en) 2006-02-01
AU2005237255B2 (en) 2011-07-07
PE20060467A1 (es) 2006-06-11
EP1747001A2 (en) 2007-01-31
NO20065499L (no) 2006-11-29
IL178458A0 (en) 2008-04-13
KR20160150113A (ko) 2016-12-28
JP2007535519A (ja) 2007-12-06
US20050250747A1 (en) 2005-11-10
JP2013018787A (ja) 2013-01-31
CA2562296A1 (en) 2005-11-10
UY28875A1 (es) 2005-11-30
US8163721B2 (en) 2012-04-24
WO2005105103A3 (en) 2006-09-08
JP6134491B2 (ja) 2017-05-24
PA8631801A1 (es) 2006-11-09
HUE041475T2 (hu) 2019-05-28
EA200601908A1 (ru) 2007-04-27
JP2017048253A (ja) 2017-03-09
EP1747001B1 (en) 2018-10-10
AU2005237255A1 (en) 2005-11-10
SV2006002100A (es) 2006-02-15
KR101812160B1 (ko) 2017-12-27
NZ586107A (en) 2012-05-25
SG152288A1 (en) 2009-05-29
DK1747001T3 (en) 2019-02-04
US20150174142A1 (en) 2015-06-25
US20120202779A1 (en) 2012-08-09
TWI374735B (en) 2012-10-21
ES2704999T3 (es) 2019-03-21
SI1747001T1 (sl) 2019-02-28
CN103127156A (zh) 2013-06-05
ECSP066999A (es) 2006-12-29

Similar Documents

Publication Publication Date Title
SG152288A1 (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
ZA200705026B (en) Manifold for use in medicament dispenser
ZA200704355B (en) Manifold for use in medicament dispenser
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
EP1762213A4 (en) A LOCKED BODY CONTAINING MEDICAMENT
SI1773296T1 (sl) Farmacevtski vagnalni gel, ki obsega tenofovir
AP2004003046A0 (en) Dosage regimen and pharmaceutical composition for emergency contraception.
IL181445A0 (en) Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium selective modulators
EP1779831A4 (en) SEALED ARTICLE WITH THE MEDICAMENT STORED IN IT
IL186656A0 (en) Extended estrogen dosing contraceptive regimen
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
IL180899A0 (en) Pharmaceutical composition comprising drospirenone and ethynylestradiol
ZA200701443B (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
UA91190C2 (ru) Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов
EP2234491A4 (en) DOSAGE SCHEMES AND PHARMACEUTICAL COMPOSITIONS AND PACKAGING FOR EMERGENCY CONTRACEPTION
JO3731B1 (ar) تدبير نزيف مفاجئ في انظمة موانع حمل هرمونية
AU2003215767A8 (en) Devices for use in medicine
CU20060204A7 (es) Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos
TW200634019A (en) Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors
GB0415154D0 (en) Transit and display packaging
GB0406014D0 (en) Pharmaceutical composition and use
GB0209874D0 (en) Devices for use in medicine
HU0500490D0 (en) Intra-uterine contraceptive
GB0406678D0 (en) Hygenic packaging
RU2006106570A (ru) Спермицидное средство